Germline alterations among Hispanic men with prostate cancer
- PMID: 35228665
- DOI: 10.1038/s41391-022-00517-6
Germline alterations among Hispanic men with prostate cancer
Erratum in
-
Correction: Germline alterations among Hispanic men with prostate cancer.Prostate Cancer Prostatic Dis. 2022 Sep;25(3):599. doi: 10.1038/s41391-022-00539-0. Prostate Cancer Prostatic Dis. 2022. PMID: 35488122 No abstract available.
Abstract
Background: Little is known about the true rate of pathogenic (P)/likely pathogenic (LP) germline alterations in Hispanic men with prostate cancer as most studies analyzing the prevalence of P/LP germline alterations were performed in a largely non-Hispanic white population (NHW).
Methods: We performed a retrospective analysis of two separate cohorts of men with prostate cancer: (1) a multicenter cohort of 17,256 men who underwent germline testing in a CLIA-certified laboratory and (2) a single-center cohort of all men eligible for germline testing between 2018 and 2020. The proportions of P/LP alterations and variants of uncertain significance (VUS) were computed. Fisher's exact test was used to compare germline alteration rates for significance. A multivariate logistic regression was performed adjusting for demographic and clinical factors to examine factors associated with germline testing.
Results: In the multicenter cohort, the rate of P/LP germline alterations among self-reported Hispanic men was 7.1%, which was lower than self-reported NHW men (9.7% vs. 7.1%, p = 0.058), but was not statistically significant. The VUS rate was significantly higher among the Hispanic cohort (21.5% vs. 16.6%, p = 0.005). In the single-center cohort, 136 Hispanic patients were eligible for testing of which 34 underwent germline testing (26.1%, N = 34/136). Of all prostate cancer patients in the single-center cohort undergoing germline testing (n = 173), the rate of P/LP alterations in Hispanic patients was not significantly different compared to NHW patients (14.7% vs. 12.2%, p = 0.77). The rate of VUS in Hispanic patients was significantly higher than that of NHW patients (20.6% vs. 7.2%, p = 0.047).
Conclusion: The P/LP germline alteration rate in our cohorts was similar between Hispanic and NHW men. The rate of VUS was significantly higher in Hispanic men, a consequence of undertesting in minority populations. These data support that Hispanic men with prostate cancer should be screened for germline testing similar to NHW men.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
References
-
- Cancer.org. 2021. Key statistics for prostate cancer | prostate cancer facts. https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html . Accessed 27 Aug 2021.
-
- Siegel DA, O’Neil ME, Richards TB, Dowling NF, Weir HK. Prostate cancer incidence and survival, by stage and race/ethnicity—United States, 2001–2017. MMWR Morb Mortal Wkly Rep. 2020;69:1473–80. - DOI
-
- Dobbs RW, Malhotra NR, Abern MR, Moreira DM. Prostate cancer disparities in Hispanics by country of origin: a nationwide population-based analysis. Prostate Cancer Prostatic Dis. 2019;22:159–67. - DOI
-
- Miller KD, Ortiz AP, Pinheiro PS, Bandi P, Minihan A, Fuchs HE, et al. Cancer statistics for the US Hispanic/Latino population, 2021. CA Cancer J Clin. 2021;71:466–87. - DOI
-
- Brandão A, Paulo P, Teixeira MR. Hereditary predisposition to prostate cancer: from genetics to clinical implications. Int J Mol Sci. 2020;21:5036. - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials